Editas and Vertex Ink Deal for Cas9 License for $50M Upfront

Editas Medicine and Vertex Pharmaceuticals have forged a $50 million deal for a licensing agreement of Editas’s Cas9 technology. In an announcement on Wednesday, Editas said Vertex will get a non-exclusive license the gene editing tech for use in medicines that target the BCL11A gene in sickle cell disease and beta-thalassemia, including Casgevy, or exagamglogene autotemcel.